MassCONNECT Final Showcase - Cycle I 2014
Monday, May 12 2014
8:00 am – 10:00 am
Location: Nixon Peabody Offices, 100 Summer Street, Boston, MA
This is an invitation to the final technology showcase for MassCONNECT’ s 2014 cycle I mentees.
Over the past ten weeks, our dedicated mentors have spent many hours brainstorming and advising the first class of this year’s innovative life-science start-ups on their business plans/models and overall strategy.
Witness their transformation as they present their bold new ideas at the showcase!
8am – 8:30am : Networking breakfast
8:30 – 8:35am: welcome remarks by MassBio and sponsor Nixon Peabody
8:35 – 8:45am: Othon Iliopoulos, MGH
8:50 – 9:00am: Retsina Meyer and Veronica Weiner, Resilience Pharma
9:05 – 9:15am: Frederico Bastos, Glucowise
9:20 – 9:30am: David Raiser and Iain McLeod, Aldatu Biosciences
9:30 – 10:00am: Networking
If you would like to register to attend, please contact Rakhshita Dhar at firstname.lastname@example.org or 617-674-5143.
Aldatu Biosciences: Improving HIV disease monitoring with innovative diagnostic tools
David Raiser & Iain MacLeod
Aldatu Biosciences (www.aldatubio.com) is using proprietary innovations in low-cost genotyping technology to improve diagnostics for HIV treatment monitoring. The growing prevalence of antiretroviral drug resistance threatens to undermine the efficacy of global HIV treatment programs, yet the tests available to detect it are inadequately sensitive and too costly to be implemented in those areas where HIV presents the greatest public health burden. Using our platform technology (PANDAA), we can overcome the technological and economic challenges of HIV monitoring to address the pressing need for a sensitive, low-cost assay that will match HIV-infected patients with effective therapy.
GlucoWise: A non-invasive glucometer for diabetics
Dr. George Palikaras, Dr. Themos Kallos & Frederico Bastos
The unique approach of GlucoWise (www.mediwise.co.uk) is the dual sensor system which utilizes completely safe, low power, high frequency radio waves to measure glucose levels. Only very recently have miniaturized and cost-effective components became available, enabling high-precision industrial applications. GlucoWise’s sensor system utilizes a nano-composite (called a meta-material) to increase the accuracy of the glucose measurements through human tissue.
MGH NewCO: Small molecule therapeutic for VHL disease by targeting HIF2a
Germline mutation in the Von Hippel-Lindau gene (VHL) leads to renal cell cancers, hypervascular tumors of the brain, adrenals and pancreas as well as erythrocytosis. These phenotypes are driven by aberrant expression of Hypoxia Inducible Factor 2a (HIF2a). Currently there is no effective medical treatment for VHL disease. Dr. Iliopoulos’ lab has developed HIF2a inhibitors, identified their mode of action and showed that these inhibitors work in vivo, using animal models of the disease. These inhibitors can be used for treatment of renal cell carcinoma and other human malignancies.
Resilience Pharmaceuticals: Prevention of PTSD leveraging a novel, innovative therapeutic
Retsina Meyer & Veronica Weiner
PTSD is a devastating illness with huge direct and indirect costs: over $30B annually in the US alone. However, there are no pharmaceutical treatments available to prevent or reverse the disorder. Based on more than five years of preclinical research at MIT, Resilience Pharmaceuticals (www.ResiliencePharma.com) is bringing the discovery of a novel molecular pathway underlying PTSD from the bench to the bedside. Our treatment has robust efficacy in a widely accepted animal model of the disorder.